{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T12:31:54Z","timestamp":1777725114125,"version":"3.51.4"},"reference-count":10,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.clml.2021.07.024","type":"journal-article","created":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T01:38:22Z","timestamp":1627263502000},"page":"873-878","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["IVAC With or Without Rituximab for Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas: Real-World Experience in the Modern Era"],"prefix":"10.1016","volume":"21","author":[{"given":"Michael J.","family":"Buege","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phuong H.","family":"Dao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Drill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9a","family":"LeVoir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terry","family":"Pak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim J.","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Straus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2021.07.024_bib0001","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1182\/blood-2014-06-538504","article-title":"How I treat Burkitt lymphoma in adults","volume":"124","author":"Jacobson","year":"2014","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.clml.2021.07.024_bib0002","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1200\/JCO.20.00303","article-title":"Multicenter study of risk-adapted therapy with dose-adjusted EPOCH-R in adults with untreated burkitt lymphoma","volume":"38","author":"Roschewski","year":"2020","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.clml.2021.07.024_bib0003","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.2698.2698","article-title":"Hyper-CVAD and rituximab for de novo Burkitt lymphoma\/leukemia","volume":"118","author":"Thomas","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.07.024_bib0004","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1093\/annonc\/mdt058","article-title":"Impact of chemotherapy regimen and rituximab in adult Burkitt lymphoma: a retrospective population-based study from the Nordic Lymphoma Group","volume":"24","author":"Wasterlid","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2021.07.024_bib0005","unstructured":"National Comprehensive Cancer Network. B-cell lymphomas (Version 1.2021). Accessed February 10, 2021. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf."},{"key":"10.1016\/j.clml.2021.07.024_bib0006","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.leukres.2005.10.002","article-title":"Modified Magrath IVAC regimen as second-line therapy for relapsed or refractory aggressive non-Hodgkin's lymphoma in developing countries: the experience of a single center in Brazil","volume":"30","author":"Pereira","year":"2006","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2021.07.024_bib0007","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/1042819031000141301","article-title":"Modified Magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity","volume":"45","author":"Lacasce","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2021.07.024_bib0008","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.07.024_bib0009","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.clml.2015.02.026","article-title":"Influence of rituximab on central nervous system relapse in diffuse large B-cell lymphoma and role of prophylaxis\u2014a systematic review of prospective studies","volume":"15","author":"Ghose","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2021.07.024_bib0010","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1007\/s00277-019-03853-1","article-title":"Immunohistochemical CD20-negative change in B-cell non-Hodgkin lymphomas after rituximab-containing therapy","volume":"99","author":"Maeshima","year":"2020","journal-title":"Ann Hematol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021003062?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021003062?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:37:27Z","timestamp":1761871047000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265021003062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":10,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S2152265021003062"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2021.07.024","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IVAC With or Without Rituximab for Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas: Real-World Experience in the Modern Era","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2021.07.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}